The global oncology biosimilars market was valued at USD 15.20 billion in 2025. The market is estimated at USD 17.60 billion in 2026 and is projected to reach USD 58.70 billion by 2036, at a CAGR of 12.8% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering loss of exclusivity timelines, price erosion, biosimilar penetration by molecule and market, development cost under revised regulatory guidance, originator lifecycle defense, the pipeline, regulation and tendering policy, pricing, the supplier landscape, and future growth opportunities.
The study covers biologics approved as highly similar to an originator cancer biologic after its exclusivity has ended. These include therapeutic monoclonal antibodies such as trastuzumab, bevacizumab, rituximab, and pertuzumab, and supportive care biologics such as pegfilgrastim and filgrastim for neutropenia, epoetin and darbepoetin for anemia, and denosumab for preventing skeletal-related events in bone metastases. Intravenous and subcutaneous products sold through hospital, retail, and specialty channels are included, as are the tender and formulary processes used to buy them.
In March 2026, the United States Food and Drug Administration (FDA) issued revised draft questions and answers that lower development costs by allowing sponsors to submit analytical data instead of some pharmacokinetic studies, to use clinical data from outside the U.S., and, in justified cases, to rely on a non-U.S. comparator, and the FDA said these changes could cut pharmacokinetic study costs by up to 50%. A separate draft guidance from October 2025 narrows the cases in which comparative efficacy studies are needed. Commercial results reflect continued expansion: Sandoz reported first-half 2026 biosimilar sales of USD 1.875 billion, a 20% rise in constant currency terms (47% in North America), and biosimilars now make up 33% of its net sales.
Price erosion is a key restraint, since hospital tenders for molecules with several approved biosimilars award largely on price, and erosion has gone well beyond early expectations, so a supplier can gain volume while its revenue on that molecule falls. Cheaper development will bring more entrants per molecule and push prices down faster. Originators are also moving patients to new formulations; Merck & Co. has launched a subcutaneous version of pembrolizumab, Keytruda Qlex, and patients on it cannot be switched to an intravenous biosimilar. Patent disputes over formulation, dosing, process, and device make launch timing uncertain, and capacity must be built years ahead without knowing the eventual price.
Denosumab in bone metastases is the leading near-term opportunity, given a large, long-treated population that had only one originator product until recently; Sandoz reported that its recent launches, including Wyost and Jubbonti, performed well. Smaller cancer biologics that were not worth developing before the regulatory changes now offer first entrants a thinner field and slower erosion. Subcutaneous presentations and devices such as prefilled syringes and autoinjectors let developers compete for converted patients, and emerging markets offer volume-led growth at low prices among patients who were previously untreated. Key trends include competition shifting to cost of goods and tender execution, formulation-based lifecycle defense by originators, and development spreading to smaller molecules.
By molecule, the oncology biosimilars market is segmented into trastuzumab, bevacizumab, rituximab, pegfilgrastim, filgrastim, denosumab, pertuzumab, epoetin & darbepoetin, checkpoint inhibitors (including pembrolizumab and nivolumab), and other molecules. Trastuzumab is expected to hold the largest share in 2026, supported by large treated breast and gastric cancer populations, high penetration in developed markets after early entry, many approved products that ensure broad supply, and long adjuvant treatment courses that sustain volume per patient. Denosumab is expected to grow at the highest CAGR, driven by its recent entry after originator exclusivity ended, the large bone metastases population, and long-term subcutaneous dosing. Checkpoint inhibitor biosimilars should add little until the later years of the forecast and then become the largest single opportunity, depending on how far originators have moved patients to subcutaneous forms.
By type, the oncology biosimilars market is segmented into therapeutic biosimilars and supportive care biosimilars. Therapeutic biosimilars are expected to account for the largest share in 2026 and to grow at the higher rate, as monoclonal antibodies used to treat cancer carry far higher value than supportive care products, further therapeutic molecules such as pertuzumab and later checkpoint inhibitors are entering competition, and adjuvant and maintenance treatment lasts a long time. Supportive care biosimilars will grow more slowly, since filgrastim, pegfilgrastim, epoetin, and darbepoetin products entered earliest, reached high penetration, and faced the deepest price cuts, although denosumab is the clear exception and the main growth source in this group.
By indication, the oncology biosimilars market is segmented into breast cancer, hematological malignancies, colorectal cancer, lung cancer, bone metastases & skeletal-related events, chemotherapy-induced neutropenia & anemia, and other indications. Breast cancer is expected to hold the largest share in 2026, as trastuzumab and pertuzumab biosimilars are used in neoadjuvant, adjuvant, and metastatic settings, the HER2-positive patient population is large, adjuvant courses are long, and multiple approved products support high uptake. Bone metastases & skeletal-related events are expected to grow at the highest CAGR, driven by denosumab biosimilars entering a setting with a single originator, a large population with bone metastases from solid tumors, and ongoing long-term dosing. Lung cancer is expected to gain momentum late in the forecast as checkpoint inhibitor biosimilars arrive.
By route of administration, the oncology biosimilars market is segmented into intravenous and subcutaneous. Intravenous products are expected to account for the largest share in 2026, since the main therapeutic antibodies are registered as infusions, cancer biologics are often given in infusion suites alongside chemotherapy, and most approved biosimilar presentations are intravenous. Subcutaneous products are expected to grow at the highest CAGR, supported by denosumab, subcutaneous trastuzumab and rituximab presentations, health system interest in freeing infusion capacity and reducing costs, and originator conversions that force developers to offer subcutaneous versions to reach switched patients.
By distribution channel, the oncology biosimilars market is segmented into hospital pharmacies, retail & specialty pharmacies, and other channels. Hospital pharmacies are expected to hold the largest share in 2026, as infused cancer biologics are given in hospitals and clinics, they are bought through hospital and group tenders, and cancer care is concentrated in specialist centers in most health systems. Retail & specialty pharmacies are expected to grow at the highest CAGR, as more treatment moves to subcutaneous products that can be given outside the infusion suite, denosumab volumes flow through specialty channels, and payers in several markets are moving biologics from the medical benefit to the pharmacy benefit, where substitution is easier to enforce.
Europe is expected to hold the largest share of the oncology biosimilars market in 2026, as it has the deepest biosimilar uptake of all regions, hospital and national tenders that reward low prices, early approval of the first oncology biosimilars, and wide prescriber acceptance. Suppliers based or active in the region include Sandoz, Fresenius Kabi, Formycon, Accord Healthcare, Alvotech, and STADA Arzneimittel. Because price erosion in Europe is deep, the region's share of market value is smaller than its share of treated patients.
North America is expected to grow at the highest CAGR during the forecast period, as penetration still has room to rise compared with Europe, newer molecules are launching, payers are steering biologics toward channels where substitution can be enforced, and FDA reforms are cutting development cost and time; Sandoz's 47% North American biosimilar growth in the first half of 2026 illustrates the gap. Asia-Pacific holds a significant share, supported by local biosimilar makers in South Korea, China, and India, such as Celltrion, Samsung Bioepis, Shanghai Henlius Biotech, Biocon Biologics, and Zydus Lifesciences, along with reimbursement decisions and low current treatment rates that make much of the growth additive. Latin America and the Middle East & Africa are smaller but growing through public tenders, with Brazil, Mexico, Saudi Arabia, and South Africa as the main markets.
The oncology biosimilars market is moderately consolidated for the earliest molecules, where a few suppliers hold most of the volume, and increasingly crowded for newer molecules as lower development requirements bring in more entrants. Companies compete on cost of goods and scale, subcutaneous and device options, tendering skill, the number of countries where a product is approved, reliable supply over multi-year hospital contracts, and the ability to launch on the earliest legal date. Leading players are focusing on molecules where they expect to be first or early, building subcutaneous presentations and devices, improving manufacturing yields to protect margins at tender prices, extending approvals to more markets, and preparing checkpoint inhibitor programs ahead of exclusivity expiry.
Key companies profiled in the report include Sandoz Group AG (Switzerland), Celltrion, Inc. (South Korea), Samsung Bioepis Co., Ltd. (South Korea), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Biocon Biologics Limited (India), Viatris Inc. (U.S.), Organon & Co. (U.S.), Fresenius Kabi AG (Germany), Accord Healthcare Limited (U.K.), Alvotech (Iceland), Shanghai Henlius Biotech, Inc. (China), Formycon AG (Germany), STADA Arzneimittel AG (Germany), and Zydus Lifesciences Limited (India).
The study covers biologics approved as highly similar to an originator cancer biologic after its exclusivity has ended. These include therapeutic monoclonal antibodies such as trastuzumab, bevacizumab, rituximab, and pertuzumab, and supportive care biologics such as pegfilgrastim and filgrastim for neutropenia, epoetin and darbepoetin for anemia, and denosumab for preventing skeletal-related events in bone metastases. Intravenous and subcutaneous products sold through hospital, retail, and specialty channels are included, as are the tender and formulary processes used to buy them.
In March 2026, the United States Food and Drug Administration (FDA) issued revised draft questions and answers that lower development costs by allowing sponsors to submit analytical data instead of some pharmacokinetic studies, to use clinical data from outside the U.S., and, in justified cases, to rely on a non-U.S. comparator, and the FDA said these changes could cut pharmacokinetic study costs by up to 50%. A separate draft guidance from October 2025 narrows the cases in which comparative efficacy studies are needed. Commercial results reflect continued expansion: Sandoz reported first-half 2026 biosimilar sales of USD 1.875 billion, a 20% rise in constant currency terms (47% in North America), and biosimilars now make up 33% of its net sales.
Market Dynamics
The staggered loss of exclusivity on high-value cancer biologics is a major driver of the oncology biosimilars market, as each expiry opens a new revenue pool: the first wave of trastuzumab, bevacizumab, and rituximab is well penetrated, pertuzumab and denosumab have followed, and checkpoint inhibitors are the largest pool still to open. Lower development requirements widen the range of molecules worth pursuing. Payers and hospitals under pressure on cancer drug budgets treat biosimilar use as a formulary and tender decision, which speeds adoption. Years of clinical use, including patients switched mid-treatment, have also removed most of the doubts about efficacy and immunogenicity that slowed early launches, so each new molecule is taken up faster than the one before.Price erosion is a key restraint, since hospital tenders for molecules with several approved biosimilars award largely on price, and erosion has gone well beyond early expectations, so a supplier can gain volume while its revenue on that molecule falls. Cheaper development will bring more entrants per molecule and push prices down faster. Originators are also moving patients to new formulations; Merck & Co. has launched a subcutaneous version of pembrolizumab, Keytruda Qlex, and patients on it cannot be switched to an intravenous biosimilar. Patent disputes over formulation, dosing, process, and device make launch timing uncertain, and capacity must be built years ahead without knowing the eventual price.
Denosumab in bone metastases is the leading near-term opportunity, given a large, long-treated population that had only one originator product until recently; Sandoz reported that its recent launches, including Wyost and Jubbonti, performed well. Smaller cancer biologics that were not worth developing before the regulatory changes now offer first entrants a thinner field and slower erosion. Subcutaneous presentations and devices such as prefilled syringes and autoinjectors let developers compete for converted patients, and emerging markets offer volume-led growth at low prices among patients who were previously untreated. Key trends include competition shifting to cost of goods and tender execution, formulation-based lifecycle defense by originators, and development spreading to smaller molecules.
Segment Analysis
The report analyzes the market by molecule, type, indication, route of administration, distribution channel, and geography, helping stakeholders identify the most attractive molecules, settings, and markets for development and launch.By molecule, the oncology biosimilars market is segmented into trastuzumab, bevacizumab, rituximab, pegfilgrastim, filgrastim, denosumab, pertuzumab, epoetin & darbepoetin, checkpoint inhibitors (including pembrolizumab and nivolumab), and other molecules. Trastuzumab is expected to hold the largest share in 2026, supported by large treated breast and gastric cancer populations, high penetration in developed markets after early entry, many approved products that ensure broad supply, and long adjuvant treatment courses that sustain volume per patient. Denosumab is expected to grow at the highest CAGR, driven by its recent entry after originator exclusivity ended, the large bone metastases population, and long-term subcutaneous dosing. Checkpoint inhibitor biosimilars should add little until the later years of the forecast and then become the largest single opportunity, depending on how far originators have moved patients to subcutaneous forms.
By type, the oncology biosimilars market is segmented into therapeutic biosimilars and supportive care biosimilars. Therapeutic biosimilars are expected to account for the largest share in 2026 and to grow at the higher rate, as monoclonal antibodies used to treat cancer carry far higher value than supportive care products, further therapeutic molecules such as pertuzumab and later checkpoint inhibitors are entering competition, and adjuvant and maintenance treatment lasts a long time. Supportive care biosimilars will grow more slowly, since filgrastim, pegfilgrastim, epoetin, and darbepoetin products entered earliest, reached high penetration, and faced the deepest price cuts, although denosumab is the clear exception and the main growth source in this group.
By indication, the oncology biosimilars market is segmented into breast cancer, hematological malignancies, colorectal cancer, lung cancer, bone metastases & skeletal-related events, chemotherapy-induced neutropenia & anemia, and other indications. Breast cancer is expected to hold the largest share in 2026, as trastuzumab and pertuzumab biosimilars are used in neoadjuvant, adjuvant, and metastatic settings, the HER2-positive patient population is large, adjuvant courses are long, and multiple approved products support high uptake. Bone metastases & skeletal-related events are expected to grow at the highest CAGR, driven by denosumab biosimilars entering a setting with a single originator, a large population with bone metastases from solid tumors, and ongoing long-term dosing. Lung cancer is expected to gain momentum late in the forecast as checkpoint inhibitor biosimilars arrive.
By route of administration, the oncology biosimilars market is segmented into intravenous and subcutaneous. Intravenous products are expected to account for the largest share in 2026, since the main therapeutic antibodies are registered as infusions, cancer biologics are often given in infusion suites alongside chemotherapy, and most approved biosimilar presentations are intravenous. Subcutaneous products are expected to grow at the highest CAGR, supported by denosumab, subcutaneous trastuzumab and rituximab presentations, health system interest in freeing infusion capacity and reducing costs, and originator conversions that force developers to offer subcutaneous versions to reach switched patients.
By distribution channel, the oncology biosimilars market is segmented into hospital pharmacies, retail & specialty pharmacies, and other channels. Hospital pharmacies are expected to hold the largest share in 2026, as infused cancer biologics are given in hospitals and clinics, they are bought through hospital and group tenders, and cancer care is concentrated in specialist centers in most health systems. Retail & specialty pharmacies are expected to grow at the highest CAGR, as more treatment moves to subcutaneous products that can be given outside the infusion suite, denosumab volumes flow through specialty channels, and payers in several markets are moving biologics from the medical benefit to the pharmacy benefit, where substitution is easier to enforce.
Regional Analysis
The report covers five regions (Europe, North America, Asia-Pacific, Latin America, and Middle East & Africa), spanning 18 countries, the Nordics, and four rest-of-region groups. The regional analysis of the oncology biosimilars market considers exclusivity timelines, approval and substitution rules, tendering and reimbursement practices, biosimilar penetration, and local manufacturing.Europe is expected to hold the largest share of the oncology biosimilars market in 2026, as it has the deepest biosimilar uptake of all regions, hospital and national tenders that reward low prices, early approval of the first oncology biosimilars, and wide prescriber acceptance. Suppliers based or active in the region include Sandoz, Fresenius Kabi, Formycon, Accord Healthcare, Alvotech, and STADA Arzneimittel. Because price erosion in Europe is deep, the region's share of market value is smaller than its share of treated patients.
North America is expected to grow at the highest CAGR during the forecast period, as penetration still has room to rise compared with Europe, newer molecules are launching, payers are steering biologics toward channels where substitution can be enforced, and FDA reforms are cutting development cost and time; Sandoz's 47% North American biosimilar growth in the first half of 2026 illustrates the gap. Asia-Pacific holds a significant share, supported by local biosimilar makers in South Korea, China, and India, such as Celltrion, Samsung Bioepis, Shanghai Henlius Biotech, Biocon Biologics, and Zydus Lifesciences, along with reimbursement decisions and low current treatment rates that make much of the growth additive. Latin America and the Middle East & Africa are smaller but growing through public tenders, with Brazil, Mexico, Saudi Arabia, and South Africa as the main markets.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with profiles of 16 leading companies.The oncology biosimilars market is moderately consolidated for the earliest molecules, where a few suppliers hold most of the volume, and increasingly crowded for newer molecules as lower development requirements bring in more entrants. Companies compete on cost of goods and scale, subcutaneous and device options, tendering skill, the number of countries where a product is approved, reliable supply over multi-year hospital contracts, and the ability to launch on the earliest legal date. Leading players are focusing on molecules where they expect to be first or early, building subcutaneous presentations and devices, improving manufacturing yields to protect margins at tender prices, extending approvals to more markets, and preparing checkpoint inhibitor programs ahead of exclusivity expiry.
Key companies profiled in the report include Sandoz Group AG (Switzerland), Celltrion, Inc. (South Korea), Samsung Bioepis Co., Ltd. (South Korea), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Biocon Biologics Limited (India), Viatris Inc. (U.S.), Organon & Co. (U.S.), Fresenius Kabi AG (Germany), Accord Healthcare Limited (U.K.), Alvotech (Iceland), Shanghai Henlius Biotech, Inc. (China), Formycon AG (Germany), STADA Arzneimittel AG (Germany), and Zydus Lifesciences Limited (India).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global oncology biosimilars market.
- Explains how loss of exclusivity, lower development requirements, payer pressure, and clinical acceptance are driving growth.
- Assesses the impact of price erosion, originator formulation changes, patent litigation, and capacity risk on supplier returns.
- Identifies high-growth opportunities across molecule, type, indication, route of administration, distribution channel, and region.
- Tracks exclusivity timelines, the biosimilar pipeline, and the outlook for denosumab and checkpoint inhibitor biosimilars.
- Benchmarks leading biosimilar developers on portfolio, presentations, market coverage, and manufacturing scale.
- Supports molecule selection, launch planning, partnering, and market entry decisions for developers, manufacturers, and investors.
Key Questions Answered
- How big is the global oncology biosimilars market today, and how will it grow through 2036?
- Why is value growth in this market running below volume growth?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will revised FDA guidance on pharmacokinetic and comparative efficacy studies change development cost and the number of entrants?
- Which molecule, type, indication, route of administration, and distribution channel segments will grow the fastest?
- How large is the denosumab opportunity in bone metastases?
- How will originator conversion to subcutaneous formulations affect checkpoint inhibitor biosimilars?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading biosimilar companies, and how do they compare on portfolio and cost position?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Oncology Biosimilars Market, by Molecule
6. Oncology Biosimilars Market, by Type
7. Oncology Biosimilars Market, by Indication
8. Oncology Biosimilars Market, by Route of Administration
9. Oncology Biosimilars Market, by Distribution Channel
10. Oncology Biosimilars Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Sandoz Group AG
- Celltrion, Inc.
- Samsung Bioepis Co., Ltd.
- Amgen Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Biocon Biologics Limited
- Viatris Inc.
- Organon & Co.
- Fresenius Kabi AG
- Accord Healthcare Limited
- Alvotech
- Shanghai Henlius Biotech, Inc.
- Formycon AG
- STADA Arzneimittel AG
- Zydus Lifesciences Limited
